Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: LCIS Clear all
Not yet recruiting Phase 1 Interventional

CAN1012 in Pre-Malignant DCIS and LCIS

NCT07408856
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
Interventions
CAN1012
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 1:01 PM EDT
Terminated Phase 2 Interventional

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

NCT00096369
View directory record Official record
Conditions
Breast Cancer
Interventions
tamoxifen citrate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
35 Years to 120 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
4
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Jul 22, 2026, 1:01 PM EDT
Terminated Phase 2 Interventional Results available

S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women

NCT00088972
View directory record Official record
Conditions
Breast Cancer
Interventions
celecoxib, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
9
States / cities
Glendale, California • Albuquerque, New Mexico • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments

NCT05810025
View directory record Official record
Conditions
Breast Cancer
Interventions
RealRisks
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 74 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Phase 2 Interventional

Ruxolitinib for Premalignant Breast Disease

NCT02928978
View directory record Official record
Conditions
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
Interventions
Ruxolitinib, Placebo (for Ruxolitinib)
Drug
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Not applicable Interventional

Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer

NCT00084669
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Sleep Disorders
Interventions
venlafaxine, zolpidem tartrate, management of therapy complications
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients

NCT01723943
View directory record Official record
Conditions
Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Psychosocial Effects of Cancer and Its Treatment, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
educational intervention, counseling intervention, psychosocial support for caregiver
Other
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

NCT01869764
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Jul 22, 2026, 1:01 PM EDT
Terminated Phase 2 Interventional Results available

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

NCT02137252
View directory record Official record
Conditions
Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma, Fatigue Related to Cancer Treatment
Interventions
Naltrexone, Sugar Pill
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Not applicable Interventional Results available

Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy

NCT01819233
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Lobular Breast Carcinoma in Situ, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer
Interventions
Behavioral dietary intervention, Therapeutic conventional surgery, Radiation therapy, Counseling intervention, Quality-of-life assessment
Behavioral · Procedure · Radiation + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

NCT01082211
View directory record Official record
Conditions
Breast Cancer
Interventions
3D-Conformal External Beam
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
57
States / cities
Peoria, Arizona • Burbank, California • Aurora, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Phase 2 Interventional

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

NCT00031720
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Hot Flushes
Interventions
soy protein, isoflavones, Tamoxifen, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
14
States / cities
Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jul 22, 2026, 1:01 PM EDT
Terminated Phase 2 Interventional

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

NCT04570956
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
Interventions
Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Evanston, Illinois • Rochester, Minnesota • Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 22, 2026, 1:01 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

NCT06062810
View directory record Official record
Conditions
Breast Cancer
Interventions
Raloxifene - Usual, Raloxifene - Study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
24 Years to 64 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Phase 2 Interventional Results available

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

NCT01849250
View directory record Official record
Conditions
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ, Paget Disease of the Breast, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Docosahexaenoic Acid, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Jul 22, 2026, 1:01 PM EDT
Recruiting No phase listed Observational

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

NCT05178498
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
Interventions
Follow-Up, Physical Examination, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 1:01 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

NCT01905046
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
27
States / cities
Duarte, California • Los Angeles, California • South Pasadena, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 22, 2026, 1:01 PM EDT
Completed No phase listed Observational Results available

Tumor: Breast Ratio Study

NCT02216136
View directory record Official record
Conditions
Breast Cancer, LCIS, DCIS
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 72 Years · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Not applicable Interventional

Lung Cancer Informational Study (LCIS)

NCT00579215
View directory record Official record
Conditions
Cancer, Enhanced Care, Decision-Making, Advance Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions
Enhance Care, Usual Care
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2009 · Synced Jul 22, 2026, 1:01 PM EDT
Terminated Not applicable Interventional

Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer

NCT00794989
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
Ground Flaxseed, No Intervention
Dietary Supplement · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jul 22, 2026, 1:01 PM EDT
Completed No phase listed Observational

Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ

NCT00581750
View directory record Official record
Conditions
Breast Cancer, Lobular Carcinoma, Invasive Breast Cancer
Interventions
Tissue specimen
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Phase 2 Interventional Results available

Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer

NCT01556243
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic conventional surgery, whole breast irradiation
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
40 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
350
States / cities
Hot Springs, Arkansas • Dublin, California • Emeryville, California + 216 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Molecular Breast Imaging in Women With Atypia and LCIS

NCT00620087
View directory record Official record
Conditions
Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
Interventions
Molecular Breast Imaging, Screening Mammography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Jul 22, 2026, 1:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

NCT01219075
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
soy isoflavones, placebo, questionnaire administration, magnetic resonance imaging, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, mammography
Dietary Supplement · Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 22, 2026, 1:01 PM EDT